

(c) whether the non declaration of Narmada and Tapti as National Waterways is likely to adversely affect inland water transport development in two important and major rivers of Gujarat?

THE MINISTER OF STATE OF THE MINISTRY OF SURFACE TRANSPORT (SHRI RAJESH PILOT): (a) Yes, Sir.

(b) and (c) Due to constraints of resources it has not been included in VII Plan. Besides, for declaring a waterway as a National Waterway Techno-economic feasibility Studies, Hydrographic Surveys and Traffic Studies are prerequisites. Accordingly, pre-feasibility Study for navigation on the Narmada and the Narmada Main Canal was carried out. The State-I of the Technical Feasibility Study and cost of methods to pass four Major Dams was also carried out with Dutch collaboration. The State II & III of the Feasibility Study to identify measures for introduction of river services through difficult stretches and financial and economic analysis respectively is yet to be undertaken. With regard to the Tapti the studies are envisaged at a later stage, in view of its low cargo potential and difficult navigability compared with other waterways identified for being considered for declaring as National Waterways.

Samples Testing of Drugs in the Country

2441. SHRI BHUBANESHWAR KALITA:

SHRI RAJNI RANJAN SAHU:

Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) what is the number of samples drawn for test from each State during last three years, year-wise about finished medicines, Sera and Vaccines;

(b) the number out of them that were tested at Central Drugs Laboratory, Calcutta alongwith the details of report in each case;

(c) what type of medicines, Sera and Vaccines are picked up from market for testing;

(d) what is the normal time taken for its report after drawing the sample;

(e) the details of action taken during last three years, year-wise in cases of medicines found sub-standard, spurious and sub-therapeutic value of medicines; and

(f) the names of medicines and Sera and Vaccines withdrawn from the market, names of manufacturers whose manufacturing licences were suspended and the action taken against the guilty firms?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (KUMARI SAROJ KHAPARDE): (a), (b) and (e) The manufacture, sale and distribution of drugs is controlled by the State Drugs Controllers under the provisions of the Drugs and Cosmetics Rules. The available information received from States in respect of samples drawn for finished medicines, Sera and Vaccines is attached at Annexure-I. [See Appendix CXLI, Annexure No. 113] Under the Drugs & Cosmetics Rules the State Governments are required to have their State Government Analyst. However, Central Drugs Laboratory, Calcutta which is statutory appellate laboratory is also a Government Analyst for 22 States/Union Territories. A statement showing results of tests/analysis as reported by Central Drugs Laboratory, Calcutta for the last 3 years is attached. (See below). Information available from the States/Union Territories on prosecution launched during the last 3 years in respect of offences relating to manufacture and sale of misbranded (spurious) drugs and adulterated drugs is attached at Annexure-II [See Appendix CXLI, Annexure No. 114]

(c), (d) and (f) All types of medicines, Sera and Vaccines are picked up from the market for testing. Drugs

& Cosmetics Rules do not lay down specific time limit for testing and reporting of sample drawn. However, samples drawn are analysed before the date of expiry, if any, and then reported. Information regarding name

of the medicines, Sera and Vaccines withdrawn from the market, names of the manufacturer etc. whose licences are suspended by State Drugs Controllers etc. is not available with the Government.

Statement

Samples tested etc. by Central Drugs Lab., Calcutta during the last 3 years.

Year	Total No. of Samples tested	No. of samples Declared Sub-standard
1983-84	4652	749 (16.10%)
1984-85	4433	584 (13.39%)
1985-86	3892	644 (65.54%)

Departmental promotions in the Unani System of I.S.M. Division

2442. SHRI RASHEED MASOOD: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether any departmental promotions have been made from amongst the officials in the Unani system of I.S.M. Division in the ministry; and

(b) if so, whether appointment of the officials have been made, and if not, what are the reasons therefor?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (KUMARI SAROJ KHAPARDE): (a) and (b) On the recommendation of the Departmental Promotion Committee, the Research Assistant (Unani) working in ISM Division was appointed as Research Officer (Unani) against the vacant post in Pharmacopoeial Laboratory for Indian Medicine, Ghaziabad which is under the Ministry of Health and Family Welfare. However, the person concerned did not join the post of Research Officer (Unani) at Ghaziabad inspite of granting him extension of time several times for joining the post in that Laboratory.

Misuse of Loan Licensing Facilities in Drug Manufacturing

2443. SHRI RAJNI RANJAN SAHU: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) what are the names of the drug manufacturing companies having their own manufacturing facilities and testing laboratories which have obtained loan licences in favour of Small Scale Units in the State of Maharashtra, Gujarat and Andhra Pradesh, who do not possess complete testing laboratories;

(b) the name of each brand of formulation alongwith composition of each;

(c) whether it is a fact that these companies are misusing the loan licensing system; and

(d) what was the reason for granting loan licences to these companies which possess their own manufacturing units?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (KUMARI SAROJ KHAPARDE): (a) to (d) Under the provisions of the Drugs and Cosmetics Act drug manufacturing licences are issued by the State